Guangzhou Improve Med Instrument (300030) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou Improve Med Instrument (300030) has a cash flow conversion efficiency ratio of 0.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥70.22 Million ≈ $10.27 Million USD) by net assets (CN¥664.29 Million ≈ $97.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangzhou Improve Med Instrument - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Guangzhou Improve Med Instrument's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Guangzhou Improve Med Instrument carry for a breakdown of total debt and financial obligations.
Guangzhou Improve Med Instrument Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou Improve Med Instrument ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huida Sanitary Ware Co Ltd
SHG:603385
|
0.035x |
|
Transcom Inc
TW:5222
|
0.029x |
|
Taiwan Steel Union Co Ltd
TW:6581
|
0.035x |
|
Ramky Infrastructure Limited
NSE:RAMKY
|
0.073x |
|
Wanxiang Doneed Co Ltd
SHG:600371
|
-0.012x |
|
Hoasen Group
VN:HSG
|
-0.084x |
|
Hes Technology Group
SHE:002963
|
0.053x |
|
Fanli Digital Technology Co Ltd
SHG:600228
|
-0.081x |
Annual Cash Flow Conversion Efficiency for Guangzhou Improve Med Instrument (2006–2024)
The table below shows the annual cash flow conversion efficiency of Guangzhou Improve Med Instrument from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Guangzhou Improve Med Instrument worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥643.86 Million ≈ $94.22 Million |
CN¥81.84 Million ≈ $11.98 Million |
0.127x | +21.26% |
| 2023-12-31 | CN¥762.33 Million ≈ $111.55 Million |
CN¥79.90 Million ≈ $11.69 Million |
0.105x | +102.49% |
| 2022-12-31 | CN¥820.61 Million ≈ $120.08 Million |
CN¥42.48 Million ≈ $6.22 Million |
0.052x | -68.94% |
| 2021-12-31 | CN¥1.03 Billion ≈ $150.78 Million |
CN¥171.74 Million ≈ $25.13 Million |
0.167x | +18.31% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.74 Million |
CN¥141.27 Million ≈ $20.67 Million |
0.141x | +140.21% |
| 2019-12-31 | CN¥838.26 Million ≈ $122.66 Million |
CN¥49.16 Million ≈ $7.19 Million |
0.059x | -14.65% |
| 2018-12-31 | CN¥815.47 Million ≈ $119.33 Million |
CN¥56.04 Million ≈ $8.20 Million |
0.069x | -53.43% |
| 2017-12-31 | CN¥963.72 Million ≈ $141.02 Million |
CN¥142.19 Million ≈ $20.81 Million |
0.148x | +507.22% |
| 2016-12-31 | CN¥954.18 Million ≈ $139.63 Million |
CN¥23.19 Million ≈ $3.39 Million |
0.024x | +381.92% |
| 2015-12-31 | CN¥930.46 Million ≈ $136.16 Million |
CN¥-8.02 Million ≈ $-1.17 Million |
-0.009x | +93.77% |
| 2014-12-31 | CN¥782.00 Million ≈ $114.43 Million |
CN¥-108.20 Million ≈ $-15.83 Million |
-0.138x | -340.89% |
| 2013-12-31 | CN¥772.70 Million ≈ $113.07 Million |
CN¥44.38 Million ≈ $6.49 Million |
0.057x | +9.57% |
| 2012-12-31 | CN¥687.93 Million ≈ $100.67 Million |
CN¥36.06 Million ≈ $5.28 Million |
0.052x | -12.56% |
| 2011-12-31 | CN¥648.25 Million ≈ $94.86 Million |
CN¥38.86 Million ≈ $5.69 Million |
0.060x | +23.11% |
| 2010-12-31 | CN¥592.55 Million ≈ $86.71 Million |
CN¥28.86 Million ≈ $4.22 Million |
0.049x | -16.93% |
| 2009-12-31 | CN¥563.53 Million ≈ $82.46 Million |
CN¥33.03 Million ≈ $4.83 Million |
0.059x | -81.36% |
| 2008-12-31 | CN¥78.73 Million ≈ $11.52 Million |
CN¥24.76 Million ≈ $3.62 Million |
0.315x | +591.31% |
| 2007-12-31 | CN¥58.27 Million ≈ $8.53 Million |
CN¥2.65 Million ≈ $387.95K |
0.046x | -86.61% |
| 2006-12-31 | CN¥19.33 Million ≈ $2.83 Million |
CN¥6.57 Million ≈ $961.54K |
0.340x | -- |
About Guangzhou Improve Med Instrument
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising urine, feces, and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The… Read more